Leptin & Ghrelin: The Hunger Hormones Explained

Written by Empire Medical Training Editorial Team

Medically reviewed by Betsy Greenleaf, DO Board-Certified OB/GYN & Urogynecologist; Empire Director of Anti-Aging

Updated June 2026 ·11 min read

Ask most patients why they struggle to lose weight and they will reach for the language of discipline — they ate too much, they lacked willpower, they fell off the plan. That framing is not only demoralizing; it is biologically wrong. As Empire faculty member Dr. Betsy Greenleaf teaches in our medical weight loss curriculum, hunger and fullness are governed by a tightly coordinated hormonal system that operates largely below conscious control. The two hormones at the center of it are leptin and ghrelin.

Understanding these hormones reframes the entire clinical conversation. It explains why obesity behaves as a chronic disease rather than a lifestyle choice, why diets tend to fail in the long run, and why a class of medications that act on satiety signaling has been so transformative. This guide is clinical education for providers, not medical advice, and nothing here is a treatment recommendation or a substitute for current evidence and labeling.

Appetite is hormonal, not willpower

The brain — specifically the hypothalamus — plays the central role in regulating hunger and satiety. It does not act in isolation; it receives and integrates signals from organs throughout the body to decide whether to seek food, how much to eat, and when to stop. The stomach reports on its own fullness and emptiness, fat tissue reports on long-term energy stores, the gut releases hormones in response to nutrients, and the brain weighs all of it against reward and habit. Appetite is the output of that integration.

This is why willpower is the wrong lens. A patient who feels relentlessly hungry on a restrictive diet is not weak; their hypothalamus is receiving a hormonal message that energy is scarce and is responding exactly as it evolved to. The clinical task is not to scold the patient but to understand and, where appropriate, modify the signals. The two most important of those signals are ghrelin, which says eat, and leptin, which says stop.

Ghrelin: the hunger hormone

Ghrelin is produced in the stomach when it is empty. It is the hormone behind the growling, hollow sensation that we recognize as hunger — the body's chemical prompt to seek out food. Ghrelin levels rise before meals, stimulating appetite, and fall after eating, which makes it the most meal-to-meal of the appetite hormones. It is short-acting and reactive: it tracks the immediate state of the stomach rather than long-term energy stores.

Because ghrelin is so directly tied to the act of eating, it has clinical consequences that are easy to overlook. Individuals can differ in their ghrelin sensitivity or in receptor activity, which means the same empty stomach can generate a much stronger drive to eat in one person than in another. And ghrelin does not stay fixed. As Greenleaf emphasizes, under certain conditions — including the aftermath of weight loss — ghrelin levels can rise, making it harder to lose weight and easier to regain it. A patient fighting elevated ghrelin is fighting a hormone whose entire job is to make food feel urgent.

Leptin: the satiety signal from fat cells

If ghrelin is the accelerator, leptin is the brake. Leptin is the fat-cell–derived hormone that regulates food intake and energy homeostasis. Adipose tissue secretes leptin, which signals the brain to reduce appetite and increase energy expenditure. In a system working as designed, more fat means more leptin, which means a stronger “you have enough stored energy” message and, in turn, less hunger.

The crucial distinction from ghrelin is timescale. Where ghrelin fluctuates meal to meal, leptin levels are proportional to body fat and change over the long term, not from one meal to the next. Leptin is the body's report on its overall energy reserves — a slow-moving thermostat rather than a moment-to-moment alarm. That long-term character is exactly why leptin sits at the heart of how the body defends its weight, and why it behaves so counterintuitively in obesity.

That counterintuitive behavior is the key. As body fat falls, leptin levels decrease — the brake is released and hunger rises. One might therefore expect people with more fat, and therefore more leptin, to feel consistently satisfied. In practice, the opposite is often true, and the reason is a phenomenon called leptin resistance.

Leptin resistance: why more fat doesn't mean less hunger

Here is the paradox at the core of appetite physiology. People with obesity usually have high leptin levels, because they have more fat cells producing it. If leptin reliably suppressed appetite, those individuals should feel persistently full. Instead, many remain hungry. The explanation is leptin resistance — a state in which the brain stops responding normally to leptin even though circulating leptin is abundant.

In leptin resistance, the satiety message is being broadcast loudly but the hypothalamus is no longer listening. The brain effectively reads a high-fat, high-leptin body as though it were starving, and keeps appetite switched on. As Greenleaf notes, leptin resistance is commonly seen in obesity, diabetes, and infertility — conditions that cluster precisely because they share this disrupted signaling. This is the single most important concept on this page: in established obesity, the problem is frequently not too little of the satiety hormone but a brain that can no longer hear it.

How dieting backfires

Once you understand leptin and ghrelin, the dismal long-term record of dieting stops being mysterious. The body defends a set point — a weight it treats as normal and works to restore. When a restrictive diet pushes weight below that set point, the body mounts a coordinated hormonal counter-regulation to claw it back.

Greenleaf describes the post–weight-loss state plainly: decreased leptin, increased ghrelin, more daytime fatigue, and less physical activity. Read that as a system: the satiety brake weakens, the hunger accelerator presses harder, energy drops so the patient moves less, and metabolic rate slows to conserve calories. Every one of those changes pushes in the same direction — toward regaining the lost fat. The patient is not imagining that food feels more tempting and willpower feels thinner after losing weight; that is the measurable hormonal reality.

The outcome follows predictably. As Greenleaf teaches, diet can produce short-term weight loss, but the majority of people regain the weight over the next two to five years, especially when the diet was restrictive. The more aggressive the deprivation, the harder the counter-regulation pushes back. This is why she stresses that there is no single perfect diet and that diets are not one size fits all — and why durable treatment of obesity has to work with this physiology rather than simply demanding more restraint against it. For more on building sustainable eating patterns, see our overview of diet for weight loss.

How this explains the GLP-1 drugs

This hormonal model is also the clearest way to understand why GLP-1 medications have been so effective where dieting alone falls short. GLP-1 agonists such as semaglutide and tirzepatide work through the incretin and satiety pathways rather than asking the patient to out-discipline their own biology.

Their mechanism maps directly onto the hormones described above. In the hypothalamus, GLP-1 agonists decrease appetite and increase the feeling of fullness after meals — in effect supplying a satiety signal pharmacologically, doing the job that resistant leptin has stopped doing. They also slow gastric emptying, so the stomach stays fuller for longer and the ghrelin-driven urge to refill arrives later. Where a restrictive diet provokes the body's counter-regulation, these drugs intervene in the very signaling that drives hunger and satiety in the first place.

That distinction also explains a well-documented clinical observation: when GLP-1 therapy is stopped, appetite signaling reverts and a substantial portion of lost weight is commonly regained. The medication does not cure leptin resistance or reset the set point; it modifies the signal while it is present. This is why GLP-1 drugs are best understood as treatment for obesity as a chronic disease rather than a temporary fix — a point covered in depth in our companion overview of weight-loss medications.

Clinical implications for providers

For clinicians, appetite physiology is not academic background — it changes how you counsel, select, and treat. A few practical implications follow directly from the leptin–ghrelin model:

• Lead with the biology, not blame. Patients who understand that hunger is hormonal are less likely to internalize regain as personal failure and more likely to stay engaged with long-term treatment.
• Expect counter-regulation and plan for it. Because leptin falls and ghrelin rises after weight loss, maintenance is its own clinical phase. Anticipating the hormonal pushback — rather than treating regain as a surprise — shapes follow-up and the decision to continue therapy.
• Treat obesity as chronic. Leptin resistance and an entrenched set point do not resolve with a single weight-loss episode, which is why durable management often resembles managing any other chronic disease.
• Match the tool to the mechanism. When willpower-based approaches repeatedly fail against the hormonal current, agents that act on satiety signaling become a rational, evidence-based option for appropriate patients.

What this overview deliberately does not provide is the protocol layer — the lab work that characterizes a patient's metabolic and hormonal status, the patient-selection criteria, the titration and monitoring schedules, and how to integrate appetite-targeting medications into a complete program. That clinical system is exactly what Empire's medical weight loss training teaches.

Training for providers

The hunger hormones are the foundation on which competent weight medicine is built. A provider who can explain leptin resistance and set-point counter-regulation in plain language — and who knows how today's medications act on those pathways — counsels better, selects patients more appropriately, and sets realistic expectations about maintenance and regain.

Empire's curriculum is built around exactly this kind of mechanistic understanding, connecting the science of appetite to dedicated medical weight loss training for clinicians who want to build or expand a weight-management practice grounded in physiology rather than in telling patients to try harder.